Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Aadi Bioscience (NASDAQ: AADI) has announced it will release its third quarter 2024 financial results and provide corporate updates on Wednesday, November 6, 2024. The company will make this information available on the Investors & News section of their website at aadibio.com.

News Market Reaction 1 Alert

+1.53% News Effect

On the day this news was published, AADI gained 1.53%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

10/30/2024 - 04:05 PM

LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

About Aadi Bioscience

Aadi is a precision oncology company focused on the commercialization of FYARRO^® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
IR@aadibio.com